HHQ16 is an orally active derivative of Astragaloside IV ( HY-N0431 ). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling.
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Others | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Drug Derivative
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.